Chembio Diagnostics, Inc. (CEMI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Chembio Diagnostics, Inc. (CEMI) Healthcare & Pipeline Overview

Chembio Diagnostics, Inc. specializes in developing and commercializing point-of-care diagnostic tests for infectious diseases. The company's portfolio includes tests for COVID-19, HIV, Syphilis, and Zika, sold under trademarks like STAT-PAK and SURE CHECK. It serves medical laboratories, hospitals, and governmental entities globally, operating in the medical diagnostics sector.

What Is the Investment Thesis for CEMI?

Chembio Diagnostics, Inc. operates in the point-of-care diagnostics market, which is expected to grow due to increasing demand for rapid and accurate disease detection. The company's focus on infectious diseases, including COVID-19, HIV, and Zika, positions it to capitalize on global health priorities. However, Chembio's negative profit margin of -48.2% indicates financial challenges. Key to the investment thesis is the company's ability to leverage its collaboration agreements with organizations like the Bill & Melinda Gates Foundation and U.S. government agencies to drive product development and market access. The company's success hinges on improving its financial performance and expanding its market share in the competitive diagnostics industry. Investors should monitor the company's revenue growth, cost management, and regulatory approvals for new tests.

Based on FMP financials and quantitative analysis

CEMI Key Highlights

• Chembio Diagnostics, Inc. develops point-of-care diagnostic tests for infectious diseases, addressing a critical need for rapid and accurate disease detection.
• The company's product portfolio includes tests for COVID-19, HIV, Syphilis, and Zika virus, targeting significant global health concerns.
• Chembio has established collaboration agreements with organizations like the Bill & Melinda Gates Foundation and U.S. government agencies, supporting product development and market access.
• The company's gross margin stands at 20.2%, indicating potential for improvement in operational efficiency.
• Chembio's market capitalization is $0.02 billion, reflecting its position as a smaller player in the diagnostics industry.

Who Are CEMI's Competitors?

CEMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CEMI's Key Strengths?

• Focus on point-of-care diagnostics for infectious diseases
• Established collaboration agreements with key organizations
• Diverse product portfolio targeting multiple diseases
• Global distribution network

What Are CEMI's Weaknesses?

• Negative profit margin (-48.2%)
• Relatively small market capitalization ($0.02B)
• Dependence on collaboration agreements for funding and development
• Competition from larger, more established diagnostics companies

What Could Drive CEMI Stock Higher?

• Potential regulatory approvals for new diagnostic tests in development.
• Expansion of existing collaboration agreements with global health organizations.
• Increasing demand for point-of-care diagnostics due to the COVID-19 pandemic.

What Are the Key Risks for CEMI?

• Financial-distress signal — its Altman Z-Score of -3.42 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-89.5%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $1.3M recently.
• Intense competition from larger diagnostics companies.
• Regulatory hurdles and delays in obtaining approvals for new tests.
• Dependence on collaboration agreements for funding and market access.
• Fluctuations in demand for COVID-19 testing as the pandemic evolves.

What Are the Growth Opportunities for CEMI?

• Expansion of COVID-19 Testing Solutions: Chembio can capitalize on the ongoing need for COVID-19 testing by expanding its product offerings and distribution channels. The global COVID-19 diagnostics market is expected to remain significant in the near term, driven by the emergence of new variants and the need for continuous monitoring. By developing more advanced and user-friendly COVID-19 tests, Chembio can capture a larger share of this market. The timeline for this growth opportunity is immediate and ongoing, as the pandemic continues to evolve.
• Leveraging Partnerships for Global Health Initiatives: Chembio's collaboration agreements with organizations like the Bill & Melinda Gates Foundation and U.S. government agencies provide a strong foundation for expanding its presence in global health initiatives. These partnerships can facilitate the development and distribution of diagnostic tests for diseases prevalent in developing countries, such as HIV, malaria, and dengue. The market for these tests is substantial, driven by the need for affordable and accessible diagnostics in resource-limited settings. The timeline for this growth opportunity is medium-term, as it requires ongoing collaboration and product development.
• Development of Multiplex Diagnostic Tests: Chembio can enhance its product portfolio by developing multiplex diagnostic tests that can detect multiple diseases simultaneously. This approach can improve efficiency and reduce costs for healthcare providers. The market for multiplex assays is growing rapidly, driven by advancements in molecular diagnostics and the increasing demand for comprehensive testing solutions. By investing in research and development in this area, Chembio can gain a competitive advantage and expand its market reach. The timeline for this growth opportunity is medium- to long-term, as it requires significant investment in technology and product development.
• Geographic Expansion into Emerging Markets: Chembio can pursue geographic expansion into emerging markets, where there is a significant unmet need for point-of-care diagnostics. These markets, such as Africa and Southeast Asia, are experiencing rapid economic growth and increasing healthcare spending. By establishing distribution networks and partnerships in these regions, Chembio can tap into new revenue streams and diversify its geographic footprint. The timeline for this growth opportunity is medium- to long-term, as it requires careful market analysis and strategic planning.
• Focus on Regulatory Approvals for New Tests: Chembio can drive growth by obtaining regulatory approvals for its pipeline of diagnostic tests. Regulatory approvals, such as those from the FDA in the United States and the EMA in Europe, are essential for commercializing new products and gaining market access. By prioritizing regulatory compliance and investing in clinical trials, Chembio can accelerate the approval process and bring new tests to market more quickly. The timeline for this growth opportunity is ongoing, as it requires continuous effort and investment in regulatory affairs.

What Opportunities Does CEMI Have?

• Expansion of COVID-19 testing solutions
• Development of multiplex diagnostic tests
• Geographic expansion into emerging markets
• Increased demand for point-of-care diagnostics

What Threats Does CEMI Face?

• Intense competition in the diagnostics industry
• Regulatory hurdles and approval processes
• Potential disruptions in supply chain
• Changes in healthcare policies and reimbursement rates

What Are CEMI's Competitive Advantages?

• Proprietary diagnostic test technologies
• Established brand recognition under trademarks like STAT-PAK and SURE CHECK
• Collaboration agreements with reputable organizations and government agencies
• Global distribution network reaching diverse customer segments

What Does CEMI Do?

Chembio Diagnostics, Inc., founded in 1985 and headquartered in Hauppauge, New York, is a medical diagnostics company focused on developing, manufacturing, and commercializing point-of-care (POC) diagnostic tests. These tests are designed to detect or diagnose various diseases quickly and efficiently. The company's product portfolio includes tests for critical diseases such as COVID-19, HIV, Syphilis, and Zika virus. Additionally, Chembio is involved in developing tests for other infectious diseases like malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. Chembio sells its products under several trademarks, including STAT-PAK, SURE CHECK, STAT VIEW, and DPP. The company utilizes a direct sales approach and also distributes its products through a network of distributors, reaching medical laboratories, hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments both in the United States and internationally. Chembio has established collaboration agreements with organizations such as the Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics. The company also partners with U.S. government agencies, including the Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. These collaborations support the development and distribution of its diagnostic tests, particularly in areas with significant unmet needs.

What Products and Services Does CEMI Offer?

• Develops point-of-care (POC) diagnostic tests for various diseases.
• Manufactures diagnostic tests for infectious diseases.
• Commercializes diagnostic tests to medical laboratories and hospitals.
• Offers tests for COVID-19, HIV and Syphilis, and Zika virus.
• Develops tests for malaria, dengue, chikungunya, and other diseases.
• Sells products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks.
• Distributes products directly and through distributors to various healthcare entities.
• Collaborates with organizations like the Bill & Melinda Gates Foundation and U.S. government agencies.

How Does CEMI Make Money?

• Develops and manufactures point-of-care diagnostic tests.
• Sells diagnostic tests directly to medical laboratories, hospitals, and governmental entities.
• Distributes products through a network of distributors.
• Generates revenue through the sale of diagnostic tests for various diseases.

What Industry Does CEMI Operate In?

Chembio Diagnostics, Inc. operates within the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for rapid and accurate testing solutions. The global point-of-care diagnostics market is driven by factors such as the rising prevalence of infectious diseases, technological advancements, and the need for decentralized testing. Chembio competes with larger, more established players in the diagnostics market. The company's success depends on its ability to differentiate itself through innovative products, strategic partnerships, and effective market penetration. The industry is also subject to stringent regulatory requirements, requiring companies to navigate complex approval processes.

Who Are CEMI's Key Customers?

• Medical laboratories
• Hospitals
• Governmental and public health entities
• Non-governmental organizations
• Medical professionals
• Retail establishments

Net sellingInsider Activity

The most recent 12 insider filings for Chembio Diagnostics, Inc. break down as 10 sales and 2 purchases. On net that is roughly 563K shares disposed (about $1.3M), a signal worth weighing alongside the fundamentals.

F-Score 5/9Financial Health

Chembio Diagnostics, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.42 places it in the distress zone, a signal of elevated financial risk.

ROE -89%Key Financial Metrics

Return on equity for Chembio Diagnostics, Inc. stands at -89.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -84.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.23 indicates the company holds enough short-term assets to cover its near-term obligations.

Chembio Diagnostics, Inc. (CEMI) Valuation Context

Valued at $16.7M, CEMI is classified as a micro-cap stock. Relative to its peer group, CEMI's quantitative score of 53/100 is roughly in line with the peer average of 53/100.

Company Profile

Chembio Diagnostics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Hauppauge, US. The company is led by CEO Richard L. Eberly. CEMI has traded publicly since 2000.

CEMI Financials

CEMI Latest News

CEMI Analyst Consensus

CEMI MoonshotScore

CEMI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources